泓博医药(301230)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

301230 泓博医药

已收盘 03-27 15:00:00

{"stockData":{"symbol":"301230","market":"SZ","secType":"STK","nameCN":"泓博医药","latestPrice":36.9,"timestamp":1774595010000,"preClose":34.97,"halted":0,"volume":6383120,"delay":0,"changeRate":0.0552,"floatShares":126000000,"shares":140000000,"eps":0.2622,"marketStatus":"已收盘","change":1.93,"latestTime":"03-27 15:00:00","open":34.49,"high":36.97,"low":34.3,"amount":231000000,"amplitude":0.0764,"askPrice":36.93,"askSize":1,"bidPrice":36.89,"bidSize":1,"shortable":0,"etf":0,"ttmEps":0.2622,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1774834200000},"marketStatusCode":5,"adr":0,"adjPreClose":34.97,"symbolType":"stock","openAndCloseTimeList":[[1774575000000,1774582200000],[1774587600000,1774594800000]],"highLimit":38.47,"lowLimit":31.47,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":139586605,"isCdr":false,"pbRate":4.76,"roa":"--","peRate":140.732265,"roe":"3.3%","epsLYR":0.12,"committee":0.442953,"marketValue":5151000000,"turnoverRate":0.0508,"status":0,"floatMarketCap":4635000000},"requestUrl":"/m/hq/s/301230","defaultTab":"news","newsList":[{"id":"2622361849","title":"3月27日泓博医药涨5.52%，长城消费增值混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2622361849","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622361849?lang=zh_cn&edition=full","pubTime":"2026-03-27 16:18","pubTimestamp":1774599508,"startTime":"0","endTime":"0","summary":"证券之星消息，3月27日泓博医药涨5.52%，收盘报36.9元，换手率5.08%，成交量6.38万手，成交额2.31亿元。重仓泓博医药的公募基金请见下表：该股最近90天内共有1家机构给出评级，买入评级1家。根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共4家，其中持有数量最多的公募基金为长城基金的长城消费增值混合A。长城消费增值混合A目前规模为4.74亿元，最新净值1.0749，较上一交易日下跌1.65%，近一年下跌2.1%。该公募基金现任基金经理为龙宇飞。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032700033494.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301230","BK0216"],"gpt_icon":0},{"id":"2621059046","title":"泓博医药：截至2026年3月20日股东户数为19,571户","url":"https://stock-news.laohu8.com/highlight/detail?id=2621059046","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621059046?lang=zh_cn&edition=full","pubTime":"2026-03-24 15:15","pubTimestamp":1774336524,"startTime":"0","endTime":"0","summary":"证券之星消息，泓博医药(301230)03月24日在投资者关系平台上答复投资者关心的问题。投资者提问：公司最新股东人数泓博医药回复：尊敬的投资者您好！根据中登公司下发的股东名册，截至2026年3月20日（交易日），公司的股东户数为19,571户。感谢关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032400019846.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301230"],"gpt_icon":0},{"id":"2620316172","title":"彩讯股份：公司暂未与泓博医药合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2620316172","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620316172?lang=zh_cn&edition=full","pubTime":"2026-03-18 17:48","pubTimestamp":1773827300,"startTime":"0","endTime":"0","summary":"证券之星消息，彩讯股份(300634)03月18日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘你好，注意到公司在布局AI制药相关方面，也注意到公司在和泓博医药有AI制药AI大模型相关的合作，泓博医药可以说是国内AI制药第一股，现在市值这么低潜力这么巨大，公司为什么不直接控股或者收购呢彩讯股份回复：尊敬的投资者，您好！公司暂未与泓博医药合作，暂无上述安排，请以公司公告为准。感谢您的关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031800032428.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0231","300634","301230","BK0216"],"gpt_icon":0},{"id":"2620427884","title":"泓博医药：围绕相关技术方向构建了以DiOrion平台为核心的药物研发体系","url":"https://stock-news.laohu8.com/highlight/detail?id=2620427884","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620427884?lang=zh_cn&edition=full","pubTime":"2026-03-17 20:52","pubTimestamp":1773751961,"startTime":"0","endTime":"0","summary":"证券之星消息，泓博医药03月16日在投资者关系平台上答复投资者关心的问题。公司围绕相关技术方向构建了以DiOrion平台为核心的药物研发体系，覆盖靶点发现、分子设计与优化、成药性预测等关键环节。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031700039720.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301230","BK0216"],"gpt_icon":0},{"id":"2620942738","title":"凯普生物：公司与您提及的泓博医药暂无相关合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2620942738","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620942738?lang=zh_cn&edition=full","pubTime":"2026-03-17 20:52","pubTimestamp":1773751934,"startTime":"0","endTime":"0","summary":"证券之星消息，凯普生物(300639)03月16日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘你好，注意到公司在布局AI制药相关方面，也注意到公司在和泓博医药有AI制药AI大模型相关的合作，泓博医药可以说是国内AI制药第一股，现在市值这么低潜力这么巨大，公司为什么不直接控股或者收购呢凯普生物回复：您好，感谢您的关注。公司与您提及的泓博医药暂无相关合作，关于公司的对外投资情况请留意公司的相关公告及定期报告。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031700039681.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301230","BK0132","BK0046","BK0042","BK0239","BK0216","300639"],"gpt_icon":0},{"id":"2619327964","title":"泓博医药：公司目前的DiOrion平台主要由公司自主研发","url":"https://stock-news.laohu8.com/highlight/detail?id=2619327964","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619327964?lang=zh_cn&edition=full","pubTime":"2026-03-16 15:07","pubTimestamp":1773644835,"startTime":"0","endTime":"0","summary":"证券之星消息，泓博医药03月15日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘您好，想了解公司与深势科技目前合作的具体进展： 1.双方在AI药物研发、分子模拟、Hermite平台、Uni-FEP计算等方面的合作推进到哪一阶段？公司与深势科技此前有过合作，相关技术也在公司早期项目中进行了应用。公司目前的DiOrion平台主要由公司自主研发，双方并未开展合作研发。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031600014261.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301230","BK0216"],"gpt_icon":0},{"id":"2619065100","title":"股市必读：泓博医药(301230)股东户数2.06万户，较上期减少2.98%","url":"https://stock-news.laohu8.com/highlight/detail?id=2619065100","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619065100?lang=zh_cn&edition=full","pubTime":"2026-03-16 02:43","pubTimestamp":1773600190,"startTime":"0","endTime":"0","summary":"截至2026年3月13日收盘，泓博医药报收于39.59元，下跌1.07%，换手率2.43%，成交量3.05万手，成交额1.21亿元。当日关注点来自交易信息汇总：3月13日主力资金净流出454.96万元，散户资金净流入498.27万元。股本股东变化股东户数变动近日泓博医药披露，截至2026年3月10日公司股东户数为2.06万户，较2月27日减少632.0户，减幅为2.98%。户均持股数量由上期的6585.0股增加至6787.0股，户均持股市值为28.04万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031600001018.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301230"],"gpt_icon":0},{"id":"2619197739","title":"泓博医药：目前不存在应披露而未披露的战略投资、股权合作等方面的重大事项","url":"https://stock-news.laohu8.com/highlight/detail?id=2619197739","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619197739?lang=zh_cn&edition=full","pubTime":"2026-03-13 20:51","pubTimestamp":1773406289,"startTime":"0","endTime":"0","summary":"证券之星消息，泓博医药03月12日在投资者关系平台上答复投资者关心的问题。目前公司不存在应披露而未披露的战略投资、股权合作等方面的重大事项。未来如涉及相关重大事项，公司将严格依据法律法规和监管要求，及时履行信息披露义务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031300038405.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301230"],"gpt_icon":0},{"id":"2619340198","title":"康龙化成：公司与泓博医药没有合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2619340198","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619340198?lang=zh_cn&edition=full","pubTime":"2026-03-13 17:24","pubTimestamp":1773393853,"startTime":"0","endTime":"0","summary":"证券之星消息，康龙化成(300759)03月13日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘你好，注意到公司在布局AI制药相关方面，也注意到公司在和泓博医药有AI制药AI大模型相关的合作，泓博医药可以说是国内AI制药第一股，现在市值这么低潜力这么巨大，公司为什么不直接控股或者收购呢康龙化成回复：尊敬的投资者您好，公司与泓博医药没有合作，对该公司情况不了解，亦无相关收购计划，感谢您的关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031300029729.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1141","03759","BK1576","300759","BK0216","301230"],"gpt_icon":0},{"id":"2618922495","title":"股市必读：泓博医药（301230）3月11日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2618922495","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618922495?lang=zh_cn&edition=full","pubTime":"2026-03-12 01:27","pubTimestamp":1773250030,"startTime":"0","endTime":"0","summary":"截至2026年3月11日收盘，泓博医药报收于40.73元，下跌1.43%，换手率2.79%，成交量3.51万手，成交额1.44亿元。公司密切关注前沿技术的发展和应用，并在药物发现领域围绕智能体方向开展了探索工作。目前上述工作尚处于内部探索阶段，暂未形成可对外披露的重大进展。当日关注点来自交易信息汇总：3月11日主力资金净流出640.64万元，散户资金净流入656.06万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031200000913.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301230"],"gpt_icon":0},{"id":"2618288947","title":"泓博医药：目前上述工作尚处于内部探索阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2618288947","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618288947?lang=zh_cn&edition=full","pubTime":"2026-03-11 20:52","pubTimestamp":1773233572,"startTime":"0","endTime":"0","summary":"证券之星消息，泓博医药03月11日在投资者关系平台上答复投资者关心的问题。公司密切关注前沿技术的发展和应用，并在药物发现领域围绕智能体方向开展了探索工作。目前上述工作尚处于内部探索阶段，暂未形成可对外披露的重大进展。公司将根据业务需求及整体规划稳步推进相关研究，请您以公司公告或定期报告发布的内容为准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031100037468.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301230"],"gpt_icon":0},{"id":"2618623303","title":"泓博医药：公司的客户及订单情况属于未公开信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2618623303","media":"证券日报 ","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618623303?lang=zh_cn&edition=full","pubTime":"2026-03-09 19:03","pubTimestamp":1773054180,"startTime":"0","endTime":"0","summary":"登录新浪财经APP 搜索【信披】查看更多考评等级\n　　证券日报网讯 3月9日，泓博医药在互动平台回答投资者提问时表示，公司的客户及订单情况属于未公开信息，敬请以公司在指定信息披露平台发布的公告和定期报告为准。（文章来源：证券日报）\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-03-09/doc-inhqkxfq0651688.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-03-09/doc-inhqkxfq0651688.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["301230","BK0216"],"gpt_icon":0},{"id":"2617557464","title":"股市必读：泓博医药(301230)股东户数2.12万户，较上期减少3.75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2617557464","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617557464?lang=zh_cn&edition=full","pubTime":"2026-03-05 01:11","pubTimestamp":1772644271,"startTime":"0","endTime":"0","summary":"截至2026年3月4日收盘，泓博医药报收于38.34元，下跌2.59%，换手率4.09%，成交量5.14万手，成交额1.99亿元。股本股东变化股东户数变动近日泓博医药披露，截至2026年2月27日公司股东户数为2.12万户，较2月13日减少826.0户，减幅为3.75%。户均持股数量由上期的6338.0股增加至6585.0股，户均持股市值为29.35万元。根据中登公司下发的股东名册，截至2026年2月27日（交易日），公司的股东户数为21,199户，目前公司股东结构保持稳定。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030500000657.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301230","BK0216"],"gpt_icon":0},{"id":"2616582729","title":"泓博医药：DiOrion平台作为公司自主研发的赋能药物研发的工具","url":"https://stock-news.laohu8.com/highlight/detail?id=2616582729","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616582729?lang=zh_cn&edition=full","pubTime":"2026-03-04 15:45","pubTimestamp":1772610325,"startTime":"0","endTime":"0","summary":"证券之星消息，泓博医药03月04日在投资者关系平台上答复投资者关心的问题。投资者提问：DiOrion平台2026年新增临床/IND项目数量与客户拓展情况？DiOrion平台作为公司自主研发的赋能药物研发的工具，目前仍在稳步迭代升级中，致力于帮助客户加速早期药物发现进程。公司目前正在编制2025年年度报告，相关经营数据及业务进展将按照监管要求在定期报告中统一披露，敬请关注公司公告。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030400023127.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301230","BK0216"],"gpt_icon":0},{"id":"2616958271","title":"泓博医药：截至2026年2月27日股东户数为21,199户","url":"https://stock-news.laohu8.com/highlight/detail?id=2616958271","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616958271?lang=zh_cn&edition=full","pubTime":"2026-03-04 15:45","pubTimestamp":1772610316,"startTime":"0","endTime":"0","summary":"证券之星消息，泓博医药(301230)03月04日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘您好，请问截至最新股东户数是多少？公司目前股东结构是否稳定？是否有应披露而未披露的重大信息？谢谢。泓博医药回复：尊敬的投资者您好！根据中登公司下发的股东名册，截至2026年2月27日（交易日），公司的股东户数为21,199户，目前公司股东结构保持稳定。公司严格按照法律法规履行信息披露义务，不存在应披露而未披露的重大信息。感谢关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030400023100.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301230"],"gpt_icon":0},{"id":"2616231011","title":"3月3日泓博医药跌7.56%，长城消费增值混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2616231011","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616231011?lang=zh_cn&edition=full","pubTime":"2026-03-03 16:59","pubTimestamp":1772528348,"startTime":"0","endTime":"0","summary":"证券之星消息，3月3日泓博医药跌7.56%，收盘报39.36元，换手率6.18%，成交量7.76万手，成交额3.16亿元。重仓泓博医药的公募基金请见下表：该股最近90天内共有1家机构给出评级，买入评级1家。根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共4家，其中持有数量最多的公募基金为长城基金的长城消费增值混合A。长城消费增值混合A目前规模为4.74亿元，最新净值1.2171，较上一交易日下跌1.96%，近一年上涨6.74%。该公募基金现任基金经理为龙宇飞。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030300029694.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301230","BK0216"],"gpt_icon":0},{"id":"2614090303","title":"泓博医药：截至2026年2月13日股东户数为22,025户","url":"https://stock-news.laohu8.com/highlight/detail?id=2614090303","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614090303?lang=zh_cn&edition=full","pubTime":"2026-02-26 15:45","pubTimestamp":1772091924,"startTime":"0","endTime":"0","summary":"证券之星消息，泓博医药(301230)02月26日在投资者关系平台上答复投资者关心的问题。投资者提问：请问最新一期公司的股东人数是多少？泓博医药回复：尊敬的投资者您好！根据中登公司下发的股东名册，截至2026年2月13日（交易日），公司的股东户数为22,025户。感谢关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022600019073.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301230","BK0216"],"gpt_icon":0},{"id":"2614033532","title":"泓博医药（301230）披露关于更换保荐代表人的公告，2月25日股价上涨0.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614033532","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614033532?lang=zh_cn&edition=full","pubTime":"2026-02-25 22:17","pubTimestamp":1772029034,"startTime":"0","endTime":"0","summary":"截至2026年2月25日收盘，泓博医药报收于44.58元，较前一交易日上涨0.29%，最新总市值为62.23亿元。该股当日开盘44.31元，最高44.79元，最低43.58元，成交额达1.91亿元，换手率为3.43%。泓博医药于近日披露《关于更换保荐代表人的公告》。公告显示，公司收到中信证券《关于更换保荐代表人的函》，因原保荐代表人王琦先生工作调整，不再担任持续督导保荐代表人，中信证券委派元彬龙先生接替其工作。公司持续督导期至中国证监会和深交所规定结束为止。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022500037991.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301230"],"gpt_icon":0},{"id":"2610995339","title":"泓博医药：截至2026年2月10日股东户数为22,411户","url":"https://stock-news.laohu8.com/highlight/detail?id=2610995339","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610995339?lang=zh_cn&edition=full","pubTime":"2026-02-12 09:03","pubTimestamp":1770858190,"startTime":"0","endTime":"0","summary":"证券之星消息，泓博医药(301230)02月11日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘，您好！请问公司截至2026年2月10日收盘，公司的股东户数是多少？谢谢。泓博医药回复：尊敬的投资者您好！根据中登公司下发的股东名册，截至2026年2月10日（交易日），公司的股东户数为22,411户。感谢关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021200006144.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301230"],"gpt_icon":0},{"id":"2608354259","title":"泓博医药(301230)1月30日股东户数2.46万户，较上期减少3.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2608354259","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608354259?lang=zh_cn&edition=full","pubTime":"2026-02-04 17:30","pubTimestamp":1770197441,"startTime":"0","endTime":"0","summary":"证券之星消息，近日泓博医药披露，截至2026年1月30日公司股东户数为2.46万户，较1月20日减少780.0户，减幅为3.07%。在医疗服务行业个股中，泓博医药股东户数低于行业平均水平，截至1月30日，医疗服务行业平均股东户数为4.63万户。从股价来看，2026年1月20日至2026年1月30日，泓博医药区间涨幅为1.82%，在此期间股东户数减少780.0户，减幅为3.07%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020400029699.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301230","BK0216"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1774648866558,"stockEarnings":[{"period":"1week","weight":0.0219},{"period":"1month","weight":-0.1723},{"period":"3month","weight":0.259},{"period":"6month","weight":0.0838},{"period":"1year","weight":0.1842},{"period":"ytd","weight":0.238}],"compareEarnings":[{"period":"1week","weight":-0.011},{"period":"1month","weight":-0.0563},{"period":"3month","weight":-0.0126},{"period":"6month","weight":0.0224},{"period":"1year","weight":0.1601},{"period":"ytd","weight":-0.0139}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"上海泓博智源医药股份有限公司","boardCode":"AI0073","boardName":"研究和试验发展","stockholders":"19571人(较上一季度减少4.84%)","perCapita":"6418股","listingDate":"2022-11-01","address":"上海市浦东新区庆达路315号23幢","registeredCapital":"13958万元","survey":"　　上海泓博智源医药股份有限公司的主营业务是药物发现、制药工艺的研究开发以及原料药中间体的商业化生产。公司的主要产品是替格瑞洛API及关键中间体、帕拉米韦中间体、左卡尼汀、奥拉西坦、本维莫德。","listedPrice":40},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"泓博医药(301230)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供泓博医药(301230)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"泓博医药,301230,泓博医药股票,泓博医药股票老虎,泓博医药股票老虎国际,泓博医药行情,泓博医药股票行情,泓博医药股价,泓博医药股市,泓博医药股票价格,泓博医药股票交易,泓博医药股票购买,泓博医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"泓博医药(301230)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供泓博医药(301230)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}